1968
DOI: 10.4269/ajtmh.1968.17.432
|View full text |Cite
|
Sign up to set email alerts
|

Recovery of Venezuelan Equine Encephalomyelitis Virus in Panamá

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
48
0
1

Year Published

1986
1986
2016
2016

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 73 publications
(50 citation statements)
references
References 0 publications
1
48
0
1
Order By: Relevance
“…Humans also develop relatively high titered viremia following epizootic virus infection [33][34][35] but are probably less important for amplification because they are less attractive and subject to far fewer mosquito bites than equines. Although human infections with enzootic VEE viruses can produce severe and sometimes fatal disease, [36][37][38] equines living near enzootic foci develop VEE-specific antibodies but apparently do not often suffer disease.…”
Section: Discussionmentioning
confidence: 99%
“…Humans also develop relatively high titered viremia following epizootic virus infection [33][34][35] but are probably less important for amplification because they are less attractive and subject to far fewer mosquito bites than equines. Although human infections with enzootic VEE viruses can produce severe and sometimes fatal disease, [36][37][38] equines living near enzootic foci develop VEE-specific antibodies but apparently do not often suffer disease.…”
Section: Discussionmentioning
confidence: 99%
“…The neuropathologic and neuroimmunologic effects of VEEV in human encephalitis cases have not been well described owing to lack of autopsy specimens. Gross pathologic analysis of 21 lethal encephalitis cases revealed cerebral edema and meningeal infiltrates comprised of neutrophils, lymphocytes, and monocytes that extend to Virchow Robbins spaces and, in some cases, CNS parenchyma [47].…”
Section: Togaviridaementioning
confidence: 99%
“…Other symptoms range from mild nausea, vomiting with decreased sensorial capability, nuchal rigidity, ataxia and convulsions, to coma and paralysis. The fatality rate in humans is about 1 % (Johnson and Martin 1974;Johnson et al 1968;Nalca et al 2003;Pittman et al 1996). Currently, no vaccine for VEEV is publicly available and the experimental military vaccine has poor efficacy (Colpitts et al 2007;Russell 1999).…”
Section: Togaviridaementioning
confidence: 99%